Article | March 8, 2021

EMA Expands Use Of Remote Source Data Verification

By Bree Burks, RN, MSN, Veeva Systems, Inc.

Blocks saying Guidance

The European Medicines Agency (EMA) has expanded the use and scope of remote source data verification (rSDV) in clinical trials. The updated guidance, now in its fourth version, justifies the use of rSDV on more trials with fewer restrictions.

This is a positive step forward for the industry as the new guidance balances patient safety with the needs of study sponsors, sites, and investigators in maintaining compliance and minimizing risk to trial integrity while dealing with disruptions caused by COVID-19.

Read how the updated guidance justifies the use of rSDV on more trials with fewer restrictions.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: